Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.

Posted · Add Comment

PURPOSE: To indentify genetic variation that can modulate and predict the risk of developing thalidomide-related peripheral neuropathy (TrPN). PATIENTS AND METHODS: We analyzed DNA from 1,495 patients with multiple myeloma. Using a custom-built single nucleotide polymorphism (SNP) array, we tested the association of TrPN with 3,404 SNPs. The SNPs were selected in predicted functional regions within 964 genes spanning 67 molecular pathways thought to be involved in the pathogenesis, treatment response, and adverse effects associated with myeloma and its therapy. Patient cases and controls were derived from two large clinical trials that compared thalidomide with conventional-based treatment in myeloma patients (Medical Research Council Myeloma-IX and HOVON-50/GMMG-HD3). RESULTS: We report TrPN […]

Genetic predisposition for chemotherapy-induced neuropathy in multiple myeloma

Posted · Add Comment

Peripheral neuropathy is one of the most frequent and debilitating adverse effects encountered by patients with cancer undergoing chemotherapy treatment. For multiple myeloma (MM), every effective regimen includes at least one agent that can cause neuropathy, a major dose-limiting toxicity in clinical trials and in clinical practice. Furthermore, neuropathy occurs even before therapy as a consequence of the disease in approximately 20% of patients with MM, and can even occur in the precursor condition, monoclonal gammopathy of undetermined significance. Authors: Becker p. et al. J Clin Oncol. 2011 Mar 1;29(7):783-6. doi: 10.1200/JCO.2010.33.4771. Epub 2011 Jan 18. Click here to view Article


Privacy Preference Center

Close your account?

Your account will be closed and all data will be permanently deleted and cannot be recovered. Are you sure?